Table 1.
Effect of TGZ and in combination with cisplatin on thoracic tumor and pleural effusion produced by MPM cells in SCID mice
| Treatment | Thoracic tumor | Pleural effusion | ||
|---|---|---|---|---|
| Incidence | Weight (mg) | Incidence | Volume (μL) | |
| Control | 5/5 | 390 (246–416) | 5/5 | 450 (250–500) |
| 250 mg/kg TGZ | 5/5 | 277 (174–398) | 5/5 | 540 (250–610) |
| 500 mg/kg TGZ | 5/5 | 313 (21–384) | 2/5 | 0 (0–650) |
| 1000 mg/kg TGZ | 5/5 | 153* (94–334) | 3/5 | 40 (0–680) |
| 3 mg/kg Cisplatin | 5/5 | 89** (57–139) | 0/5 | 0** |
| 6 mg/kg Cisplatin | 5/5 | 16** (11–18) | 0/5 | 0** |
| 3 mg/kg Cisplatin+500 mg/kg TGZ | 5/5 | 82** (22–180) | 0/5 | 0** |
EHMES‐10 cells were inoculated into the thoracic cavity of SCID mice on day 0. Treatments were started 1 week after orthotopic implantation. Experimental groups included: control (0.5% carboxymethyl cellulose [CMC] in sterile water per day, by gavage), troglitazone (TGZ) alone (250, 500, and 1000 mg/kg per day, by gavage), cisplatin alone (3 and 6 mg/kg per week, by intraperitoneal injection), and a combination of TGZ (500 mg/kg per day, by gavage) and cisplatin (3 mg/kg per week, by intraperitoneal injection). Four weeks after tumor cell inoculation, the mice were dissected and thoracic tumors and pleural effusions were evaluated as described in the Materials and Methods. Data are expressed as median with ranges in parentheses. *P < 0.05 compared with control; **P < 0.01 compared with control. MPM, malignant pleural mesothelioma, SCID, severe combined immunodeficient.